Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 8.13 is 59% below its 5-year average of 19.82, near the low end of its 5-year range (3.18–51.16).
As of the fiscal period ended Tuesday, June 30, 2026. 31.86% below its 12-month average of 11.93.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.13.
QUICK RATIO (ACID-TEST)
8.13
QUICK RATIO (ACID-TEST) AVG TTM
11.93
QUICK RATIO (ACID-TEST) AVG 3Y
15.85
QUICK RATIO (ACID-TEST) AVG 5Y
19.82
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-31.86%
CURRENT VS 3Y AVG
-48.70%
CURRENT VS 5Y AVG
-58.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+142.34%
vs the sector median at left
Atea Pharmaceuticals, Inc.
Market Cap
$405.74M
Quick Ratio (Acid-Test)
8.13
TTM Avg
11.93
3Y Avg
15.85
5Y Avg
19.82
Market Cap
$406.58M
Quick Ratio (Acid-Test)
9.89
TTM Avg
6.34
3Y Avg
6.34
5Y Avg
6.34
Market Cap
$404.24M
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.95
3Y Avg
1.91
5Y Avg
2.07
Market Cap
$402.17M
Quick Ratio (Acid-Test)
10.64
TTM Avg
18.70
3Y Avg
14.71
5Y Avg
15.03
Market Cap
$411.00M
Quick Ratio (Acid-Test)
2.64
TTM Avg
6.72
3Y Avg
6.86
5Y Avg
10.10
Market Cap
$411.21M
Quick Ratio (Acid-Test)
16.52
TTM Avg
13.61
3Y Avg
8.86
5Y Avg
8.86
Market Cap
$397.99M
Quick Ratio (Acid-Test)
8.66
TTM Avg
7.11
3Y Avg
5.24
5Y Avg
5.24
Market Cap
$396.93M
Quick Ratio (Acid-Test)
8.92
TTM Avg
6.16
3Y Avg
7.06
5Y Avg
7.06
Market Cap
$415.98M
Quick Ratio (Acid-Test)
9.44
TTM Avg
11.90
3Y Avg
14.34
5Y Avg
23.42
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | $405.74M | 8.13 | 11.93 | 15.85 | 19.82 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $406.58M | 9.89 | 6.34 | 6.34 | 6.34 |
| Myriad Genetics, Inc. (MYGN)vs › | $404.24M | 1.98 | 1.95 | 1.91 | 2.07 |
| Neurogene Inc. (NGNE)vs › | $402.17M | 10.64 | 18.70 | 14.71 | 15.03 |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.00M | 2.64 | 6.72 | 6.86 | 10.10 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | 16.52 | 13.61 | 8.86 | 8.86 |
| Carlsmed, Inc. (CARL)vs › | $397.99M | 8.66 | 7.11 | 5.24 | 5.24 |
| Shoulder Innovations, Inc. (SI)vs › | $396.93M | 8.92 | 6.16 | 7.06 | 7.06 |
| Rezolute, Inc. (RZLT)vs › | $415.98M | 9.44 | 11.90 | 14.34 | 23.42 |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | 6.40 | 3.40 | 4.68 | 4.62 |
Quick Ratio
8.13
Excludes inventory
Current Ratio
8.13
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 8.13 |
| 2026-03-31 | 7.89 |
| 2025-12-31 | 7.82 |
| 2025-09-30 | 16.66 |
| 2025-06-30 | 19.17 |
| 2025-03-31 | 19.94 |
| 2024-12-31 | 24.85 |
| 2024-09-30 | 19.33 |
| 2024-06-30 | 19.02 |
| 2024-03-31 | 13.28 |
| 2023-12-31 | 18.24 |
| 2023-09-30 | 31.93 |
| 2023-06-30 | 38.42 |
| 2023-03-31 | 51.16 |
| 2022-12-31 | 35.77 |
| 2022-09-30 | 43.62 |
| 2022-06-30 | 27.46 |
| 2022-03-31 | 24.93 |
| 2021-12-31 | 13.58 |
| 2021-09-30 | 3.22 |
| 2021-06-30 | 3.18 |
| 2021-03-31 | 3.30 |
| 2020-12-31 | 2.73 |
| 2020-09-30 | 10.02 |
| 2020-06-30 | 16.78 |
| 2020-03-31 | 9.13 |
| 2019-12-31 | 9.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
